Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. - Wikidata - awgldk - TriplyDB

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

http://www.wikidata.org/entity/Q37523265

about

Current Trends of Renal Impairment in Multiple Myeloma Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management Neuropathic cancer pain: What we are dealing with? How to manage it?International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma: comparison with serologic data.Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.Anti-angiogenesis therapies: their potential in cancer management Immunomodulatory drugs in multiple myeloma.Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.The use of novel agents in multiple myeloma patients with hepatic impairment.Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma.A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report.Thalidomide and its analogues in the treatment of Multiple Myeloma Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management.ESRD due to Multiple Myeloma in the United States, 2001-2010.Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1 Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.Role of thalidomide in previously untreated patients with multiple myeloma.Treatment of newly diagnosed myeloma.Targeting inflammatory pathways in chronic lymphocytic leukemia.Role of autologous and allogeneic stem cell transplantation in myeloma.Initial therapy in multiple myeloma: investigating the new treatment paradigm.

P2860

Q26740444-D6243B0D-3081-4A85-AE0E-5B4BAF00A05F Q26767418-8CD36489-BF8A-4054-BFF6-36961437DC0F Q26822754-446C4B44-65D4-4DB8-BFCA-EB21073BA884 Q26998884-813585DF-C7F3-4112-95B8-E2A39F7207A4 Q26998945-6843B3C3-1017-4284-B1FF-A46E8E14EA0C Q27002668-04C486F8-4471-4B9F-B6E8-BD1EC0C34F63 Q30433139-CB68B173-452A-46DA-9B23-A14AEE1D7B81 Q30669943-63C2B5B4-DE5D-4CBE-AA21-852760BA07CD Q33405119-A625C3B5-9B85-4351-BCB5-46D713A0C67E Q33424264-DD47F936-81E6-465A-BAB7-2E6A72322C63 Q33680252-10A04463-67AF-47C4-A28D-FC66DD3009A9 Q33828783-2C405047-4453-4AD0-A3B7-C0E4A8EEB1A9 Q33956056-2CB172C9-5590-4E0C-A6FD-D95F2878AF75 Q34325722-CE912168-DD90-4582-8293-CAC58AC1B9C0 Q34480149-47660892-7003-4F19-8D55-99CC74419985 Q34990174-B0E0814F-68BF-4B27-AB91-17EB9AD6EDD4 Q35153760-AD493CE6-1F0F-4DE9-A466-1BBBC3D9CA3A Q35182819-69D3EFE6-E02F-482E-AFC6-8030A065AECB Q35794472-21DF5114-88FD-47A4-AAB8-1EAE473D3D4F Q35907767-E437C43A-5E48-424E-804E-6533A396731B Q35932505-328B5585-FE31-4F52-8461-A29D090BDC5B Q36012111-1CA1171C-39B1-431E-9938-BF2AECA694F0 Q36141664-E205AE54-4F86-4CE8-BDD9-61E372BEABA7 Q36406118-A56643FA-2D45-4392-88AE-49C8D190C074 Q36444523-3CED1EFF-D2BA-48EF-B27D-03EB80E5902D Q36548083-DF462C67-9D35-487B-AF47-51C8ACF35F85 Q36570256-CA8906B6-7CF7-4159-8075-CB555E970FC2 Q36612613-8197C084-EEEB-4E53-8980-5CFB1A90DF30 Q36754816-EC9DEADD-45BF-4F7E-9B80-48B7755AB030 Q36777233-B52F4578-F42A-4903-848E-BC6954396257 Q36849170-B95AAACF-08A1-49A8-801D-86B1867F687F Q36915777-A2C28C99-A0D9-4352-8069-D6014D61BAD3 Q37038711-1660EAFC-8120-4294-BD0E-479ABAB00D94 Q37275721-24FCBE04-7BEB-4189-962F-8F7FAD83D530 Q37280739-F64C2BCD-7BDE-448E-89F7-3D86699BB3A1 Q37300004-CFF1DE82-EF40-434A-8A4F-67CA78D6A2CD Q37324251-8AEE7AC8-1DF5-476B-9CB6-FED80523E4D9 Q37351312-0809DB79-3C68-4AC6-B5EA-9AFCD9858A55 Q37391117-B252C708-E496-43DA-A626-7EA35AF31AB6 Q37411805-66190ED4-F58B-4C43-A2BD-10176817919E

P2860

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

http://www.wikidata.org/entity/Q37523265

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@en

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@nl

type

label

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@en

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@nl

prefLabel

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@en

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@nl

P1433

Q37523265-AD808F4D-8387-49F8-84C4-928A0FBDA15A

P1476

Q37523265-79FE5552-B3F6-4342-BFF5-344510BDBC91

P2093

Q37523265-0886677A-24A7-496D-8C5A-D21F3742B40E

Q37523265-169D90A6-BC87-4B2B-AED3-F556DE902044

Q37523265-212FE840-746A-4F75-9B4F-FC215E30F918

Q37523265-3AA7490E-051C-46FB-BAAD-01DBF925B20A

Q37523265-722ECB8B-DE0D-4B8B-8B71-53E05CFD5D81

Q37523265-8E64E4D9-DCD3-476F-A3A5-6B03E70F1318

Q37523265-9F7F2B5E-AC7C-4642-869C-697806F1D1B2

Q37523265-F0E8674C-ECE5-48F8-9621-57DCE9BCA554

Q37523265-F47352D1-AE72-4B8C-8182-45DC0727EDCE

P2860

Q37523265-002C58F2-2498-48E7-A725-CF1B1294E62F

Q37523265-052A2C0D-6B9C-42A8-9D92-9DB65BB600AE

Q37523265-123ABE58-06A7-4776-B7FD-572048E1030E

Q37523265-1925788C-34E6-4B82-9543-868F9092DD86

Q37523265-19EF3E46-4CB2-410B-BB49-25AB2B5B563B

Q37523265-1A3B4799-DB0C-4A6A-B064-72CCE52F45E9

Q37523265-260E477A-D736-4B04-A4C1-AD83F2F9FBFC

Q37523265-29C12825-5659-4C58-83DB-6843866BFE68

Q37523265-34F45CE4-F3D4-45BD-9169-945CEA37883A

Q37523265-373B5DF6-6B75-4F13-B2C9-809BBF455D76

P304

Q37523265-904B9C80-907A-49BB-A594-8C7BC13F37C0

P31

Q37523265-7331BCC2-7E20-4935-8D43-E40DA88BF809

P356

Q37523265-24A4E3B4-0F69-4883-8E11-CB641D81953F

P407

Q37523265-09C86143-12E0-42A2-A5F2-5027D495635A

P433

Q37523265-89384A86-C328-425E-8486-135A156D49AC

P478

Q37523265-C5DB7403-5F78-48CB-86B5-7D368D60375E

P50

Q37523265-1BA5D276-97F2-4237-A3E5-1D53BC4D76A3

Q37523265-B1732929-0D6C-4559-AEC2-29DB44AC0D24

P577

Q37523265-12475725-D471-4738-BC66-B95685CEC996

P5875

Q37523265-573879AA-FA3D-42EF-BC8C-618D84836167

P698

Q37523265-BBB8C326-72D4-456C-80E6-EC4B4C3AFE5E

P921

Q37523265-32DCBC2D-6CB8-403B-A531-FA4D8B15E9A4

Q37523265-3648278E-4D6B-4CA5-A968-9965334FC429

Q37523265-5697A76E-0E11-46EB-B759-9399B369A596

Q37523265-F4BAD6D4-5F74-4E6D-8743-1661740B7D7D

P932

Q37523265-C275E18E-5FBF-45FD-89F8-374DCE5EE0B8

P356

JCO.2007.14.1853

P1433

Journal of Clinical Oncology

P1476

Multicenter, randomized, doubl ...... ly diagnosed multiple myeloma.

@en

P2093

Jerome B Zeldis

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

John Catalano

http://www.w3.org/2001/XMLSchema#string

Laura Rosiñol

http://www.w3.org/2001/XMLSchema#string

Lela Lucy

http://www.w3.org/2001/XMLSchema#string

Marta Olesnyckyj

http://www.w3.org/2001/XMLSchema#string

Mohamad Hussein

http://www.w3.org/2001/XMLSchema#string

Robert Knight

http://www.w3.org/2001/XMLSchema#string

Zhinuan Yu

http://www.w3.org/2001/XMLSchema#string

P2860

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Antitumor activity of thalidomide in refractory multiple myeloma.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Multiple myeloma.

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.

International uniform response criteria for multiple myeloma.

Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

P304

2171-2177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.14.1853

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

S. Vincent Rajkumar

Wiesław Jędrzejczak

P577

2008-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5490731

http://www.w3.org/2001/XMLSchema#string

P698

18362366

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

3904367

http://www.w3.org/2001/XMLSchema#string